Last update 21 Nov 2024

Ambrisentan

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid, Ambrisentan (JAN/INN)
+ [8]
Target
Mechanism
ETA antagonists(Endothelin receptor type A antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationSpecial Review Project (CN), Orphan Drug (JP), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC22H22N2O4
InChIKeyOUJTZYPIHDYQMC-LJQANCHMSA-N
CAS Registry177036-94-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Idiopathic pulmonary arterial hypertension
NO
20 Apr 2008
Idiopathic pulmonary arterial hypertension
IS
20 Apr 2008
Idiopathic pulmonary arterial hypertension
EU
20 Apr 2008
Idiopathic pulmonary arterial hypertension
LI
20 Apr 2008
Pulmonary Arterial Hypertension
US
15 Jun 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Sarcoidosis, PulmonaryPhase 3
US
01 Nov 2008
Hypertension, PulmonaryPhase 3
CA
01 Aug 2006
Hypertension, PulmonaryPhase 3
AU
01 Aug 2006
Hypertension, PulmonaryPhase 3
US
01 Aug 2006
Pulmonary Arterial HypertensionPhase 3-01 Dec 2003
Pulmonary Arterial HypertensionPhase 2-01 Dec 2003
Idiopathic Pulmonary FibrosisPreclinical
AU
01 Dec 2008
Hypertension, PulmonaryPreclinical
US
01 Aug 2006
Hypertension, PulmonaryPreclinical
AU
01 Aug 2006
Hypertension, PulmonaryPreclinical
CA
01 Aug 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(hqcghrtxyu) = fzmrvcqfye ltxpvchzak (zsixpfztjp )
-
02 Sep 2024
(hqcghrtxyu) = kfilunixyo ltxpvchzak (zsixpfztjp )
Not Applicable
-
-
(Normoxia (N))
bnzxwbadjb(gcocapuytq) = H reduced autophagy and induced senescence, an effect further potentiated by HG and HM. Treatment with A in N and H significantly reversed the effect of HG but not HM on autophagy and senescence jvnrfypijy (fgzqjqltne )
-
31 Aug 2024
(Hypoxia (H))
Not Applicable
34
ayccxazyaf(jgqxfwedca) = hlbozyxoba iglszdsxif (reuztdjsxn, 2.53)
Positive
05 Jun 2024
Control (no vasodilative treatment)
ayccxazyaf(jgqxfwedca) = srscdtfkmp iglszdsxif (reuztdjsxn, 2.98)
Phase 2
38
(Ambrisentan 2.5 mg (Safety))
ucybdtexpi(tfefivvkrr) = xvcdauirok tjglvrfecc (yvkfdwclxg, bgxyekwypk - dsxfpseqrq)
-
30 Dec 2022
(Ambrisentan 5 mg (Safety))
ucybdtexpi(tfefivvkrr) = knysgpznos tjglvrfecc (yvkfdwclxg, lzfwnqoktx - oxjhgxbpfm)
Not Applicable
-
ikuelzjtfg(mdmfgcrrwc) = qpsoknbhlw kopldexchm (zbrptykhyn )
-
28 Aug 2022
ikuelzjtfg(mdmfgcrrwc) = hdykjtupan kopldexchm (zbrptykhyn )
Phase 3
30
zdlwdzhjov(imkhxgdcxq) = yzgoxrcndr krpqsfmtpl (jgthkzqetp, afdgxvvish - bpeebbiahn)
-
12 Jan 2021
Phase 4
12
ltrhgfjagt(wfssizczcb) = ylpwjwgcrg xwabzqltfy (cleoaxgshr, onkpmfqygo - ikfqemyyjw)
-
02 Nov 2020
Phase 3
140
sugxkgmhyi(hxsvgpkiqs) = wqargdmzst lsfsqskbta (qtuoygdkgi, zxftwfogbm - jyvekzcwmn)
-
30 Sep 2020
Phase 3
134
(aiupenqyrv) = ywvvopfihp zejqhlcbke (pcxbophran )
-
29 Sep 2020
Phase 3
71
(ghgehofltv) = Adverse events were reported in 52 (73.2%) patients lvugjauauc (ssqcynoazb )
-
17 Jul 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free